Key points are not available for this paper at this time.
The predictive role of hematological markers in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with pembrolizumab remains unclear.
Hagiwara et al. (Wed,) studied this question.